dr. tam on the toxicities of ibrutinib plus venetoclax in mcl
Published 7 years ago • 201 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:08
dr. tam on the toxicity of ibrutinib plus venetoclax in mcl
-
1:56
dr. tam on the combination of ibrutinib plus venetoclax in mantle cell lymphoma
-
1:02
dr. tam on zanubrutinib vs ibrutinib research in mantle cell lymphoma
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
3:18
sympatico: safety and efficacy of ibrutinib plus venetoclax for r/r mcl
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
1:10
dr. hamlin on toxicities associated with ibrutinib and buparlisib in mcl, fl, and dlbcl
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
0:47
dr. davids on remaining questions with umbralisib/ibrutinib in cll and mcl
-
1:09
dr. ritchie on the immunologic impact of long-term venetoclax/ibrutinib in r/r mcl
-
2:00
preliminary results of the aim trial of ibrutinib and venetoclax in mantle cell lymphoma
-
1:22
dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
0:15
copy of dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:16
dr. wierda on ibrutinib plus venetoclax in cll
-
0:26
acalabrutinib plus venetoclax and rituximab in the treatment of mcl
-
0:56
dr. eyre on results of venetoclax in relapsed/refractory mcl
-
2:16
dr. ruan discusses btk inhibitors in mcl
-
3:42
acalabrutinib plus venetoclax and rituximab in mcl & the importance of chemotherapy-free regimens